Assessing Patient-Reported Outcomes
Transcript of Assessing Patient-Reported Outcomes
![Page 1: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/1.jpg)
Assessing Patient-Reported Outcomes:
Health related Quality of Life (HRQOL)
Juhee Cho, Ph.D
Department of Health Science & Technology, SAIHST
Sungkyunkwan University
![Page 2: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/2.jpg)
What are Patient-Reported Outcomes (PROs)?
• A patient-reported outcome is the measurement of any aspect of a patient’s health status that comes directly from the patient (i.e., without the interpretation of the patient’s responses by a physician or anyone else).
![Page 3: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/3.jpg)
Patient Outcomes Assessment
![Page 4: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/4.jpg)
Why PROs are Important?• Unique perspective on treatment
effectiveness.• Physiological assessments often do not reflect
how a patient functions or feels (e.g., FEV1)
• May be more reliable than informal interview
• Some treatment effects are known only to the patient
• patient’s symptoms (e.g., fatigue, depression)• how well the patient feels• how well the patient functions• how the patient perceives care/treatment
![Page 5: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/5.jpg)
Question
• PROs and HRQoL is of diminishing importance in the era of emerging targeted therapies?
– True?
– False?
![Page 6: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/6.jpg)
Why?
• Cancer often an incurable illness
• Improvement in patient’s HRQoL is an expectation of appropriate therapy
• Palliation is often the goal
• HRQoL is the product of Patient Reported Outcomes
![Page 7: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/7.jpg)
PROs are Important Endpoints
• PROs are used in clinical trials to
– Describe patients & disease severity
– Trial eligibility
– Treatment effects
– Converge with other outcomes
– Risk/Benefit Evaluation
![Page 8: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/8.jpg)
PRO Domain Hierarchy
Mental Health
Physical Health Symptoms
Pain
Other
Social Health
Role Participation
Social Support
Fatigue
Positive Psychological Functioning
Cognitive Function
Anxiety
Anger/Aggression
Depression
Alcohol & Substance Use
Negative Impacts of illness
Emotional Distress
Subjective Well-Being (positive effect)
Positive Impacts of Illness
Meaning and Coherence (spirituality)
Mastery and Control (self-efficacy)
Performance
Satisfaction
HealthPRO
Satisfaction
Satisfaction
Satisfaction
Function/Disability
Upper Extremities (ADL): walking, arising, etc.
Central (ADL): neck & back (twisting, bending)
Activities: IADL (e.g. errands)
Lower Extremities (ADL): grip, buttons, etc
![Page 9: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/9.jpg)
1. What is HRQOL?
2. What Should You Measure?
3. How Should You Measure it?
4. How is it incorporated into clinical research
Health-Related Quality of Life (HRQOL) Assessment
![Page 10: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/10.jpg)
![Page 11: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/11.jpg)
Health Related Quality of Life (HRQoL)
• Includes a number of domains– Physical functioning: ranges from normal
to complete impairment
– Psychological well-being (depression, anxiety, fear of recurrence)
– Social functioning
![Page 12: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/12.jpg)
HRQoL Dimensions
Physical Functioning Spirituality
Occupational/Role Functioning Future Orientation
Social Functioning Sexuality/Intimacy
Emotional Well-being Health Concerns
Symptom Status Family Well-Being
Financial Concerns Satisfaction w/Care
Global/Overall Perception of Quality of Life
![Page 13: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/13.jpg)
P. Ganz, personal communicationt
![Page 14: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/14.jpg)
HRQOL
FunctionalStatus
GlobalRatings
Symptoms
Quality of Life
![Page 15: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/15.jpg)
What Should You Measure?
HRQOL Assessment
![Page 16: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/16.jpg)
Definitions
• Instrument = Questionnaire
• “Item” = Question
• “Domain” = Dimension= Area of Behavior or Experience
• “Cross-Sectional Design”Compares 2 or More Populations at One Point in Time
• “Longitudinal Design”Assesses Changes in HRQOL Over Time in 1 or More Populations
![Page 17: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/17.jpg)
![Page 18: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/18.jpg)
Types of QOL Instruments
• Health profiles-descriptive questionnaires-measures by a simple metric different aspects of HRQoL across multiple domains
• Generic, multi-dimensional
• Disease-specific, multi-dimensional
• Condition-specific, multi-dimensional
![Page 19: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/19.jpg)
HRQOLHRQOL
SymptomsFunctional
Status
GlobalRatings
![Page 20: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/20.jpg)
uMeasure of Functioning
Focus May be Genericor Disease-Specific
Functional Status
![Page 21: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/21.jpg)
Domain Specific
Linear Analog Self-AssessmentPlace an “X” at a point on the line that best represents how you have felt over the past two weeks.
Your Mood
Happy MiserableX
![Page 22: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/22.jpg)
Simple Average
Sum or Mean of Item or Subscale Scores to Yield a Global Score
This Approach Weights each Item Proportional to its Variance in the
Population Under Study
Example: Quality of Life Index
Aggregated Scores
![Page 23: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/23.jpg)
Symptoms
•Focus:
– Disease (e.g., asthma, CHF, cancer, lung cancer)
– Type of symptom (e.g., pain)
•Dimension(s):
– Frequency
– Severity
– Distress
– Interference with activities
![Page 24: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/24.jpg)
Single Assessment of Overall Health or HRQOL
Global Ratings
Example: E-V-G-F-PHow would you describe your overall state of health [CHECK ONE]?
Excellent
Very Good
Good
Fair
Poor
![Page 25: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/25.jpg)
Why Should You Measure It?
HRQOL Assessment
![Page 26: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/26.jpg)
Operational Definition
HRQOL Assessment Adds Value IF HRQOL Data Can Influence
Overall Conclusions of the Study
HRQOL: Value Added
![Page 27: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/27.jpg)
Nature of the Value Added Depends on Overall Study Goals
• evaluating the effectiveness of interventions
• characterizing treatment-specific outcomes for use in shared decision making
• characterizing the burden of illness
• predicting patient outcomes
• quality-adjusting survival for resource allocation and other policy decisions
Study Goals
![Page 28: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/28.jpg)
Question
HRQoL is relevant to which type(s) of clinical trials:
a. Phase I
b. Phase Ib/II
c. Randomized phase II trial
d. Prospective randomized trial
e. All of the above
![Page 29: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/29.jpg)
Depends On
1. Phase of the Trial
2. Natural History of Disease
Evaluating Effectiveness
![Page 30: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/30.jpg)
Type of Clinical Trial and PRO
• Phase I: not critical-goal is primarily to define MTD or optimal biologic dose
• Phase II: can be used but not essential
– An opportunity to collect pilot data for use in phase III trial
• Phase III-HRQOL data is essential in this
context
![Page 31: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/31.jpg)
Tailoring study design to thenatural history of the disease
3 paradigms:
– Chronic and/or recurrent, non-lethal diseases
– Lethal but curable diseases
– Lethal, incurable diseases
![Page 32: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/32.jpg)
Information Patients Need
Nature of Alternative TreatmentsLikely Outcomes from Treatments
Descriptive Information forEach of the Possible Outcomes
simple, transparent measures
Supporting SharedDecision Making
![Page 33: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/33.jpg)
Characterizing theBurden of Illness
To “Benchmark” Study Populationgeneric health status measures
To Identify Patient Needsdomain-specific measures
symptom-specific measures
![Page 34: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/34.jpg)
Predicting Outcomes
Baseline HRQoL has been Shown to be an independent Predictor for
survival & response to therapy
Breast Cancer
Lung Cancer
functional status & resource use (chronic illness)
![Page 35: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/35.jpg)
How Should You Measure It?
Identify the Respondent
patientsurrogate
provider (MD, RN, other)
HRQoL Assessment
![Page 36: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/36.jpg)
How Should You Measure It?
Choose the Domains to be Measured
disease or domain-specific instrumentgeneric instrument
global assessment of QoL
uIdentify the Respondent
HRQoL Assessment
![Page 37: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/37.jpg)
How Should You Measure It?
Consider the Need for Interpretability
health state descriptionstranslating numeric into clinical differences
uIdentify the RespondentuChoose the Domains to be Measured
HRQoL Assessment
![Page 38: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/38.jpg)
How Should You Measure It?
Choose a Mode of Administration
in person, by phone, mailedcomputer assisted (in person or phone)
self-administered (forms, computer)
uIdentify the RespondentuChoose the Domains to be MeasureduConsider Need for Interpretability
HRQoL Assessment
![Page 39: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/39.jpg)
HRQoL Instruments
• Multi-dimensional HRQoL instruments are available that cover the basic HRQoL domains
– Generic
– Cancer-specific
– Domain-specific
![Page 40: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/40.jpg)
HRQoL Instruments
• Generic types
– Intended for use across broad chronic disease populations
• Allow comparisons across these groups
• Disadvantage: may not permit adequate cancer-specific focus
– Disease caused symptoms
– Treated related symptoms
![Page 41: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/41.jpg)
도 HADS POMS SF-36 QL index SIP NHP ferrans래
.우울사
신치료
상태, 변
다 한 Health outcome 사 .
만 질 health outcome
다 한 Health outcome 사 .
반건강 사
반QoL 사
항수
14 항 65 항 36 항 5 항 136 항 45 항 64 항
상시간
2-3 − 건강한사람: 3-5, 5-7
− : 20
5-10 1 20-30 5-15 8-10
수 0~3(수 우울,
)
0~4(수심리 )
0~100지가능
하 , 수다.
3 point categorical scaling.
수가낮수낮 편.
한버
Validation Validation Validation Validation
비고 짧 시간에숙달 술없 도하게검사가능.
도 고, 다 어에피험가 답에어 움 느낀다는단 .
가 범하게쓰 는도 .하지만말들에게는
쓸수없다.
사 간편하다.건강한사람에게는쓸수없다.
다차원특 지니고 나
항많
사및 시실 지못함
건강및 능수행 만 , 사 경만 , 심리만 및가계 만등 하역
Generic HRQOL Tools
![Page 42: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/42.jpg)
HRQoL Instruments• Cancer-specific instruments
– Responsive to disease-related changes
– Cannot be used across populations with chronic disease
• Several are in common use because they are reliable and have been validated:
– Functional Living Index-Cancer: Shipper;JCO (1984); 2:427-483
• Modular instruments: combine a generic or “core” instrument with cancer-type specific questions
– FACT-C Gunnars, Acta Oncologica (2001);40:175-84.
– EORTC QLQ-C30, Aaronson JNCI (1993);85:365-367.
![Page 43: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/43.jpg)
도 CARES FACT-G FLIC EORTC QLQ-30 RSCL
신 , 신체 사(clinical & research)
functional state, well being
치료법에라 functional res
ponse 차 가는지사
Clinical trial 에health ou
tcome 사
Clinical research에참여한상사 .
항수
Original: 93-132항Short form: 38-57항
27 항 22 항 30 항 38 항
상시간
Long form 18 5 하 10 하 15 하 10 하
수 0~4 5 척도 5 리커트척도, 수가 수 삶질
7 척도 VAS 4 척도, 7 척도 4 척도.
한버
Validation Validation
비고 상생 과재에 , 재 , 결생 , , 가포함 질병과치료
한 상생내 포함
신체 역, 사 /가역, , 능 역 역에걸쳐포 평가
생에 반 능수 평가, 신체심리 및사능등 포
global health status 항 과 능평가항 주 상항, 에한다 가지 상항 과 가지각하는재 담항지포함하여평
가.
psychological 측과everyday activity 측 하고, 여러상 사
Generic HRQOL Tools for Cancer
![Page 44: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/44.jpg)
HRQoL Instruments
• Domain Specific Instruments
– Designed to address one specific aspect of HRQoL
– Examples:
• Multi-dimensional Fatigue Inventory (MFI)
• McGill Pain Questionnaire
![Page 45: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/45.jpg)
Uses of HRQoL Instruments
• Outcome measure
– RCT evaluating treatment outcomes
– To qualify quantity of survival (e.g.,cost-effectiveness)
– Assess late physical/psychological problems
• Predictor
• Intervention
![Page 46: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/46.jpg)
• Collaboration
• Cross-cultural validation
– Permission from developer
– Translation-back translation
– Pilot study
– Confirm
– Filed testing
– Psychometric validation
Cross-cultural aspect
![Page 47: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/47.jpg)
English Chinese United StatesPhysical Mental Physical Mental Physical Mental
PF 0.60 0.14 0.75 0.03 0.85 0.12
RP 0.85 0.12 0.78 0.25 0.81 0.27
BP 0.46 0.53 0.53 0.51 0.76 0.28
GH 0.14 0.74 0.32 0.66 0.69 0.37
VT 0.15 0.84 0.16 0.83 0.47 0.64
SF 0.49 0.56 0.48 0.56 0.42 0.67
RE 0.77 0.18 0.62 0.36 0.17 0.78
MH 0.12 0.83 0.10 0.86 0.17 0.87
SF-36 Factor Analysis in Singapore vs. US
![Page 48: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/48.jpg)
![Page 49: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/49.jpg)
Other Considerations
• Is the proposed analysis too taxing for the subject?
– must questionnaire be completed serially in light of possible attrition
– Is a proxy needed?
• Will population include children, low literacy, non-English speaking, visually impaired, or cognitively impaired adults?
HRQOL Assessment
![Page 50: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/50.jpg)
Other Considerations (cont’d)
• Timing of assessments– consistency across patients/groups critical– responses influenced by recent experiences
• Missing data– avoid at all costs– generally cannot be assumed to be at random– specify methods for dealing in advance!
• Multiple comparisons– specify primary endpoints in advance
HRQOL Assessment
![Page 51: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/51.jpg)
Make Your Final Choice
• Psychometric (responsive, valid, reproducible) properties
• Validated in your population
• Known and used in your field
HRQOL Assessment
![Page 52: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/52.jpg)
근간 생 가
• 검진 진단 가
• 간 해 학 해
• 간 에 한병태생리 연 발
• 상진단술
• 청학 진단법 발달
• 수술방법및수술 발
![Page 53: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/53.jpg)
하지만…다 에비해…
• 재발 & 낮 생
• 수술후간 에 한사망 험
• 여러가지합병 발생
치료가능성보다는치료 합병증을 최소화하면서
정상적인 생활을 위한간암환자의 삶의 질 측면이중요하게 인식되고 있음
![Page 54: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/54.jpg)
삶 질평가도 (Liver cancer specific module)
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:559–564
![Page 55: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/55.jpg)
Physical issue
• Lower physical well-being• Lower overall HRQOL• Pain• Sleep problem• Fatigue• Nausea• Sexual problems• Loss of appetite and weight• Difficulties digesting food• Decreased ability to perform usual activities
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:559–564
![Page 56: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/56.jpg)
Quality of Life Research 2007;16:203-215
Physical well-being
Functional well-being
Overall quality of life
![Page 57: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/57.jpg)
Treatment issue (TACE, RT)
Annals of Oncology 2006;17:304-312
Hepatobiliary cancer subscale
Functional Assessment of Cancer Therapy-Hepatobiliary
FACT-Hapatobiliary Symptom Index
![Page 58: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/58.jpg)
Clinical level issueBetter Child-Puch
Classification
Higher albumin levels
Lower serum bilirubin levels
Lower serum cholinesterase levels
Advance stage
Tumor recurrence
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:559–564
Worse HRQOL
Better HRQOL
![Page 59: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/59.jpg)
Psychological issue
Psycho-oncology 2013;22:2372–2378
![Page 60: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/60.jpg)
Psycho-oncology 2013;22:2372–2378
상 우울집단별 나뉘어보간 비
18.4% 가
![Page 61: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/61.jpg)
Psycho-oncology 2013;22:2372–2378
연 참여 반 및 상 사항보 하여도 에비해간 가
3.5배 우울하다고느꼈
![Page 62: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/62.jpg)
삶 질연 한
• 최근 연구의 부재
• 대부분의 신체적 문제와 삶의 질에 관한연구임
• 심리사회적 문제에 따른 삶의 질 영향에 관한연구가 필요함
• 신체적 문제와 심리적 문제의 관련성과이들이 환자의 삶의 질에 어떠한 영향을미치는지에 대한 연구가 필요함
![Page 63: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/63.jpg)
Methodological Challenges
• The variety of questionnaires available
• Choice of time points
• Incomplete data (data attrition)
• Lack of pre-defined endpoints
• Response-shift over time of patient perceptions of HRQoL
• Psychological defenses tend to conserve perception of good HRQoL
![Page 64: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/64.jpg)
1. Integration of QOL outcomes in cancer clinical trials is challenging
2. Anticipation of design, data collection, and analysis will decrease some problems
3. Additional resources are required to incorporate QOL outcomes successfully-budget for them!
CONCLUSIONS:
![Page 65: Assessing Patient-Reported Outcomes](https://reader031.fdocuments.net/reader031/viewer/2022012519/61941a3bae397f4e3a5541b3/html5/thumbnails/65.jpg)
Despite the Uphill Climb…we’re getting there